Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Wat na ABLYNX welke aandeln kunnen veel groeien om welke redenen.

3 Posts
| Omlaag ↓
  1. [verwijderd] 1 februari 2018 11:34
    Merus, bispecifieke antibodies zijn de toekomst. bivoorbeeld: Basel, June 28, 2016 - Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.

    Traditional monoclonal antibodies target and bind to a single antigen. Bispecific antibodies are engineered to recognize and target two different antigens, which makes them potentially more effective in targeting complex diseases. A T-cell engaging bispecific antibody is able to bind an antigen on a tumor cell with one arm and engage T-cells capable of their destruction with the other.
3 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 915,21 +0,10%
EUR/USD 1,0850 +0,04%
FTSE 100 8.317,59 -0,26%
Germany40^ 18.697,70 +0,02%
Gold spot 2.339,49 +0,24%
NY-Nasdaq Composite 16.920,79 +1,10%

Stijgers

VIVORY...
+63,57%
TKH
+3,65%
CM.COM
+3,05%
RENEWI
+2,44%
NSI
+2,41%

Dalers

JUST E...
-3,69%
AZERION
-3,41%
Galapagos
-1,79%
WDP
-1,47%
PostNL
-1,43%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links